BRCA2 and breast cancer: The aim of this review was to investigate the impact of HR deficiency in BC, focusing on BRCA mutations and their impact on modulating responses to platinum and PARPi therapy, and to share the experience of Unidade Local de Saúde Santa Maria in the management of metastatic BC patients with DNA damage targeted therapy, including those with the Portuguese c.156_157insAlu BRCA2 founder mutation.